Strides Pharma: US-Led Global Fund Cut Hurts; Greater Focus On Ex-US Markets
Strides Pharma aims for higher revenues from Canada and other ex-US markets while waiting for controlled substances to ramp up gradually under the leadership of ex-Apotex CEO Peter Hardwick. However, a cut in US funding for the Global Fund is hurting the company and its competitors.
Generics Bulletin - February 5, 2026

Consumer Health And Wellness Market Outlook: What Trends Will Impact Self-Care In 2026?
In contributed commentary, Susan Levy, SBL Consulting Group founder and principal, discusses likely health and wellness market developments which would reflect a steady shift toward more accessible, consumer-centric models of care complementing traditional healthcare.
HBW Insight - February 5, 2026

Valbiotis Enters Women’s Health Arena With Menopause Supplement
French firm's new supplement combines seven ingredients to offer relief from common menopause symptoms.
HBW Insight - February 5, 2026

US FDA’s Failure To Implement Key Workforce Reforms Puts Oversight At Risk, GAO Says
Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.
HBW Insight - February 5, 2026

CDRH Highlights Harmonization Progress In International Assessment Report
The US FDA has published its annual international harmonization assessment for fiscal 2025, which reports on the device center’s progress in aligning medical device regulations with global standards to improve patient access to safe, innovative technologies.
Medtech Insight - February 5, 2026

Execs On The Move: January 26–30, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - February 5, 2026

Midi Health Gains Unicorn Status With $100M Funding Round; Adds Serena Ventures, Foresite Capital
Women’s health start-up Midi Health has raised $100m in a Series D financing, led by Goodwater Capital with new investors Foresite Capital and Serena Ventures. Midi, which focuses on women in midlife, said the money will support the next phase of growth.
Medtech Insight - February 5, 2026

Kashiv Biosciences Expands Latin American Footprint Through Saya Biologics Partnership
A biosimilar collaboration between Kashiv and Saya aims to expand access to affordable supportive oncology therapies in Mexico and 10 additional Central America and Caribbean markets.
Generics Bulletin - February 5, 2026

Krka Doubles Down On Vertical Integration With €140m Investment Push
Slovenia’s Krka is ramping up capital spending to expand global manufacturing capacity, betting that industrial scale and supply resilience will drive its next phase of growth.
Generics Bulletin - February 5, 2026

Amgen Benefits From US Biosimilar Monopoly With $700m Sales For Pavblu
Amgen has revealed just how significant its first-mover advantage on biosimilar aflibercept has been in the US, with the firm’s Eylea rival bringing in sales of $700m in 2025 and helping to push Amgen’s annual biosimilars turnover up by more than a third to $3bn.
Generics Bulletin - February 5, 2026

APAC Regulatory Update: Prevention, Access and Digital Integration Define Regional Momentum
Featuring: Prevention?driven reforms in Vietnam; surging demand for OTC and herbal based interventions in China; Singapore updates its health data infrastructure; regional regulatory harmonization across Australia, Singapore and Indonesia; and WHO sets formal direction for TCIM.
HBW Insight - February 5, 2026

Everest Bags APAC Rights To Micot’s First-In-Class Peptide
Everest Medicine obtains selected commercialization rights to first-in-class, Phase III stage bispecific peptide MT1013 from Shanxi Micot Technology at home. A trial for secondary hyperparathyroidism is due to be completed by year-end in China.
Scrip - February 5, 2026

Update On ADCs: Sales, Deals, Targets And Approvals
The antibody-drug conjugate pipeline has more than doubled to 895 candidates since 2023, with DNA topoisomerase I overtaking HER2 as the dominant target.  
In Vivo - February 5, 2026

Chinese AI-Driven Drug Developers Rake In VC/PE Funds
Among the Chinese AI firms raising new funding, Deep Intelligent Pharma has bagged a total of $110m in two rounds of funding since last December, while Levinthal, OxTium and Aureka have also closed new investment rounds.
Scrip - February 5, 2026

Estée Lauder Pays Fine For Violating Canadian Law Over Cosmetic PFAS
The Estee Lauder Companies, Inc. pleaded guilty to two counts of violating a Canadian Act that had required it to correct missteps related to selling products containing PFAS.
HBW Insight - February 5, 2026

New York Congressional Delegation Member Slams State’s Age-Restricted Supplement Sales Law
“Dietary Supplement Regulatory Uniformity Act” would prohibit states from adding requirements and rules for supplement manufacturing and sales on top of FDA regulations.
HBW Insight - February 5, 2026